Pfizer secures China approval for GLP-1 weight-loss drug Xianweiying
Pfizer (NYSE:PFE) significantly expanded its metabolic footprint on Friday, announcing that Chinese regulators have approved its GLP-1 receptor agonist, Xianweiying (ecnoglutide), for long-term weight management in overweight and obese adults.










